Related Experiment Video
Updated: Jun 6, 2026
12:03
In Vivo Model for Testing Effect of Hypoxia on Tumor Metastasis
Published on: December 9, 2016
Current therapeutic approaches in metastatic and recurrent ewing sarcoma
1Division of Pediatric Hematology/Oncology, Department of Pediatrics, H085, Penn State Milton S. Hershey Medical Center, Penn State College of Medicine, Penn State Hershey Children's Hospital, 500 University Drive, P.O. Box 850, Hershey, PA 17033-0850, USA.
Sarcoma
|December 15, 2010
Summary
Ewing sarcoma (ES) survival has improved for localized cases but remains poor for metastatic or recurrent disease. This review covers current and potential therapies for this rare bone cancer.
Area of Science:
- Pediatric Oncology
- Skeletal Malignancies
- Cancer Therapeutics
Background:
- Ewing sarcoma (ES) is a rare primary bone cancer affecting children and young adults.
- Localized ES survival rates exceed 70% due to chemotherapy and local treatments.
- Metastatic or recurrent ES shows limited survival improvement.
Purpose of the Study:
- To review current therapeutic strategies for Ewing sarcoma.
- To discuss novel and emerging treatment options for advanced ES.
Main Methods:
- Literature review of existing Ewing sarcoma treatment protocols.
- Analysis of chemotherapy regimens, stem cell transplantation, and immunotherapy.
Main Results:
- Aggressive chemotherapy and local control improve outcomes for localized disease.
- Limited progress in survival for metastatic or recurrent Ewing sarcoma.
Conclusions:
- Current treatments offer improved outcomes for localized Ewing sarcoma.
- Further research into novel therapies like immunotherapy is crucial for advanced disease.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
02:30Metastasis
Metastasis is the spread of cancer cells from the original site to distant locations in the body. Cancer cells can spread via blood vessels (hematogenous) as well as lymph vessels in the body.
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
Epithelial-to-Mesenchymal Transition
The epithelial-to-mesenchymal transition or EMT is a developmental process commonly observed in wound healing, embryogenesis, and cancer metastasis. EMT is induced by transforming growth factor-beta (TGF-β) or receptor tyrosine kinase (RTK) ligands, which further...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...